Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. Nierengarten MB. Cancer 2023;129:1466.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer 2023;129:1466.
PMID: 37088994